Dutch biotech startup CryoCloud secures €500K funding: Know more 

Utrecht-based CryoCloud, a biotech startup, announced that it has secured €500,000 in a pre-seed round of funding led by Nina Capital, with significant contributions from Utrecht Health Seed Fund and ROM Utrecht Region.

The company will use the funds to accelerate growth and forge partnerships with leading companies and key opinion leaders. The Dutch firm will also use the capital to expand the capabilities of its platform, better-supporting scientists and streamlining data analysis.

Robert Englmeier, CEO of CryoCloud, states, “The landscape and throughput of cryo-EM has evolved significantly in the last six years, yet the way data is analysed remained the same – leading to bottlenecks and creating entrance barriers. Our mission is to make cryo-EM more accessible and to streamline the research process, which is now possible with our platform.”

CryoCloud: Developing data analysis platform

Founded by Robert Englmeier, Ilja Gubins, and Boy Persoon in 2021, CryoCloud has developed a proprietary data analysis platform — cryoEM.

The cloud-based data analysis platform enables the fast and scalable determination of 3D protein structures used for drug discovery.

Consequently, it addresses the critical challenges faced by the scientific community, including the high costs, complexity, and inefficiencies associated with traditional cryo-EM compute infrastructure.

By offering scalable cloud storage and data analysis workflows through a user-friendly web app, the Dutch company is making advanced research tools more accessible to scientists worldwide.

The company’s cloud-based data analysis platform is accessible via a subscription-based web application and is used globally by scientists at universities, biotechs & cryo-EM facilities. 

CryoCloud is based in Utrecht, the Netherlands, where Robert Englmeier and Ilja Gubins conducted their PhD studies in applied and computational cryoEM, respectively. 

The investor

Nina Capital is a specialised venture capital firm investing exclusively in the intersection of healthcare and technology. 

Marta-Gaia Zanchi, Founder & Managing Partner at Nina Capital says, “CryoCloud’s innovative approach to leveraging cloud technology in cryo-EM is not just a major step for structural biology, but a testament to the transformative power of digital solutions in the life sciences sector.”

Utrecht Health Seed Fund (UHSF) is an early-stage life sciences & health investment fund based out of Utrecht, The Netherlands. It is focused on scalable technologies in the fields of Life Sciences (therapeutics and diagnostics), Medical Devices, Digital Health, and Animal Health in the earliest stages of development. 

“We are happy to invest in CryoCloud’s solutions, to make the complex and costly process of CryoEM analysis more accessible to researchers,” says Timo Koopmans, Investment Manager at the Utrecht Health Seed Fund. “Their platform has the potential to greatly expand the use of CryoEM in the life sciences.”